drugset

drugset / Trial / NCT00598104

Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma

NCT00598104 ↗

Phase 1/2 Withdrawn Novartis

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma

Timeline

Start: 2008-01
Primary completion: 2008-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QAX576	Monoclonal antibody	—	Intravenous

Indications